Heron Therapeutics, Inc.
HRTX
$1.36
-$0.05-3.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.78% | 12.43% | 13.57% | 12.13% | 15.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.78% | 12.43% | 13.57% | 12.13% | 15.60% |
| Cost of Revenue | -26.49% | -39.48% | -44.80% | -47.55% | -41.77% |
| Gross Profit | 47.13% | 114.62% | 231.84% | 388.72% | 8,078.50% |
| SG&A Expenses | 1.70% | -9.31% | -16.14% | -31.56% | -27.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.11% | -22.74% | -29.19% | -38.68% | -34.01% |
| Operating Income | 104.28% | 94.48% | 87.61% | 92.79% | 78.24% |
| Income Before Tax | 98.07% | 90.38% | 87.72% | 76.64% | 64.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 98.07% | 90.38% | 87.72% | 76.64% | 64.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.07% | 90.38% | 87.72% | 76.64% | 64.77% |
| EBIT | 104.28% | 94.48% | 87.61% | 92.79% | 78.24% |
| EBITDA | 113.67% | 98.03% | 89.97% | 94.93% | 79.88% |
| EPS Basic | 98.12% | 91.67% | 89.72% | 81.09% | 72.34% |
| Normalized Basic EPS | 103.04% | 92.16% | 89.73% | 93.01% | 81.74% |
| EPS Diluted | 94.51% | 90.50% | 89.72% | 81.09% | 72.34% |
| Normalized Diluted EPS | 101.25% | 91.42% | 89.73% | 93.01% | 81.74% |
| Average Basic Shares Outstanding | 1.96% | 7.50% | 13.47% | 21.70% | 28.68% |
| Average Diluted Shares Outstanding | 9.18% | 15.13% | 13.47% | 21.70% | 28.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |